TransCode Therapeutics is a biopharmaceutical company focused primarily on developing and commercializing drugs and diagnostics for treating and identifying metastatic disease. Co.'s primary therapeutic candidate, TTX-MC138, targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. Co.'s other preclinical programs include two solid tumor programs: TTX-siPDL1, a small interfering RNA (siRNA)-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. The RNAZ average annual return since 2021 is shown above.
The Average Annual Return on the RNAZ average annual return since 2021 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether RNAZ average annual return since 2021 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the RNAZ average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|